Use of anti‐CMV immunoglobulins in lung transplant recipients: The French experience
Rational Pending the authorization of new anti‐CMV drugs with fewer adverse effects, exploring the possibilities offered by CMV immunoglobulins (CMVIG) seems necessary. In France, access to CMVIG requires official authorization by the national Health authority and is restricted to second line rescue...
Gespeichert in:
| Veröffentlicht in: | Transplant infectious disease 2021-12, Vol.23 (6), p.e13754-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 6 |
| container_start_page | e13754 |
| container_title | Transplant infectious disease |
| container_volume | 23 |
| creator | Charlotte, Roy François, Parquin Jonathan, Messika Véronique, Boussaud Olivier, Brugière Tristan, Degot Séverine, Feuillet Jérôme, Lepavec Adrien, Tissot Claire, Dromer Espérie, Burnet Eve, Camps Antoine, Roux |
| description | Rational
Pending the authorization of new anti‐CMV drugs with fewer adverse effects, exploring the possibilities offered by CMV immunoglobulins (CMVIG) seems necessary. In France, access to CMVIG requires official authorization by the national Health authority and is restricted to second line rescue therapy for CMV infection/disease. The aim of this multicenter retrospective study is to describe the indications and clinical situations that justified its use in France.
Methods
A multicenter retrospective study included 22 lung transplant patients over a 3‐year period. Data on clinical indication, tolerance and efficacy were collected.
Results
The main indication for CMVIG initiation, which was documented in 17 of them (82%) was complex clinical situations resulting from side effects to antiviral drug. CMVIG indication was documented as treatment for 15 patients (68%) and as a secondary prophylaxis for 7 patients (32%). Only one side effect (pruritus during infusion with no anaphylactic symptoms) attributable to CMVIG was reported. After CMVIG initiation, no recurrence of infection or disease was observed during a median follow‐up of 174 (12–682) days after treatment initiation for respectively 68% and 66% of the patients.
Conclusion
This study describes an unusual indication of CMVIG use as a last resort treatment in complex situations, based on clinical needs. CMVIG could be useful to change the course of CMV infection with minimal adverse effects or comorbidity. |
| doi_str_mv | 10.1111/tid.13754 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03524598v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2591218528</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3874-44da630c308656d0965172f101bb98a8685558507eb9515a78c8b5f62dcab7533</originalsourceid><addsrcrecordid>eNp1kctO3DAUhq0KVOjQRV-gssQGFgFf4lt3aLhKU7EZ2FqO4zBGiZPaCZcdj9Bn7JPUw1AqVerZnKNfn_5zjn4AvmB0hHMdj74-wlSw8gPYxVSpgiJOtl5nWRAi6A74lNI9QlioUn0EO7QUhJaI7YLbm-Rg30ATRv_r5ef8-y30XTeF_q7tq6n1IUEfYDuFOzhGE9LQZhJGZ_3gXRjTN7hcOXgeXbAr6J4GF7Ns3R7Ybkyb3Oe3PgM352fL-WWxuL64mp8sCkulKIuyrA2nyFIkOeM1UpxhQRqMcFUpaSSXjDHJkHCVYpgZIa2sWMNJbU0lGKUzcLjxXZlWD9F3Jj7r3nh9ebLQaw1RRkqm5APO7MGGHWL_Y3Jp1J1P1rX5I9dPSROmMMGSEZnR_X_Q-36KIX-iCceEK0SQ-rvcxj6l6Jr3CzDS62B0Dka_BpPZr2-OU9W5-p38k0QGjjfAo2_d8_-d9PLqdGP5GyzPlUc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2612690209</pqid></control><display><type>article</type><title>Use of anti‐CMV immunoglobulins in lung transplant recipients: The French experience</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Charlotte, Roy ; François, Parquin ; Jonathan, Messika ; Véronique, Boussaud ; Olivier, Brugière ; Tristan, Degot ; Séverine, Feuillet ; Jérôme, Lepavec ; Adrien, Tissot ; Claire, Dromer ; Espérie, Burnet ; Eve, Camps ; Antoine, Roux</creator><creatorcontrib>Charlotte, Roy ; François, Parquin ; Jonathan, Messika ; Véronique, Boussaud ; Olivier, Brugière ; Tristan, Degot ; Séverine, Feuillet ; Jérôme, Lepavec ; Adrien, Tissot ; Claire, Dromer ; Espérie, Burnet ; Eve, Camps ; Antoine, Roux</creatorcontrib><description>Rational
Pending the authorization of new anti‐CMV drugs with fewer adverse effects, exploring the possibilities offered by CMV immunoglobulins (CMVIG) seems necessary. In France, access to CMVIG requires official authorization by the national Health authority and is restricted to second line rescue therapy for CMV infection/disease. The aim of this multicenter retrospective study is to describe the indications and clinical situations that justified its use in France.
Methods
A multicenter retrospective study included 22 lung transplant patients over a 3‐year period. Data on clinical indication, tolerance and efficacy were collected.
Results
The main indication for CMVIG initiation, which was documented in 17 of them (82%) was complex clinical situations resulting from side effects to antiviral drug. CMVIG indication was documented as treatment for 15 patients (68%) and as a secondary prophylaxis for 7 patients (32%). Only one side effect (pruritus during infusion with no anaphylactic symptoms) attributable to CMVIG was reported. After CMVIG initiation, no recurrence of infection or disease was observed during a median follow‐up of 174 (12–682) days after treatment initiation for respectively 68% and 66% of the patients.
Conclusion
This study describes an unusual indication of CMVIG use as a last resort treatment in complex situations, based on clinical needs. CMVIG could be useful to change the course of CMV infection with minimal adverse effects or comorbidity.</description><identifier>ISSN: 1398-2273</identifier><identifier>EISSN: 1399-3062</identifier><identifier>DOI: 10.1111/tid.13754</identifier><identifier>PMID: 34723405</identifier><language>eng</language><publisher>Denmark: Wiley Subscription Services, Inc</publisher><subject>alternative therapeutics ; Anaphylaxis ; Antiviral agents ; Antiviral Agents - adverse effects ; CMV ; CMVIG ; Cytomegalovirus ; Cytomegalovirus Infections - drug therapy ; Cytomegalovirus Infections - prevention & control ; Health services ; hematological toxicity ; Humans ; Immunoglobulins ; Immunoglobulins - therapeutic use ; Immunoglobulins, Intravenous - adverse effects ; Immunological tolerance ; Indication ; Infections ; Life Sciences ; Lung ; lung transplant, rescue treatment ; Lung transplantation ; Lung Transplantation - adverse effects ; Lung transplants ; Lungs ; Patients ; Prophylaxis ; Pruritus ; Retrospective Studies ; Side effects ; Signs and symptoms ; Transplant Recipients</subject><ispartof>Transplant infectious disease, 2021-12, Vol.23 (6), p.e13754-n/a</ispartof><rights>2021 Wiley Periodicals LLC</rights><rights>2021 Wiley Periodicals LLC.</rights><rights>Copyright</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3874-44da630c308656d0965172f101bb98a8685558507eb9515a78c8b5f62dcab7533</citedby><cites>FETCH-LOGICAL-c3874-44da630c308656d0965172f101bb98a8685558507eb9515a78c8b5f62dcab7533</cites><orcidid>0000-0003-2123-3527 ; 0000-0001-8274-7180 ; 0000-0002-3259-6430</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Ftid.13754$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Ftid.13754$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34723405$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03524598$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Charlotte, Roy</creatorcontrib><creatorcontrib>François, Parquin</creatorcontrib><creatorcontrib>Jonathan, Messika</creatorcontrib><creatorcontrib>Véronique, Boussaud</creatorcontrib><creatorcontrib>Olivier, Brugière</creatorcontrib><creatorcontrib>Tristan, Degot</creatorcontrib><creatorcontrib>Séverine, Feuillet</creatorcontrib><creatorcontrib>Jérôme, Lepavec</creatorcontrib><creatorcontrib>Adrien, Tissot</creatorcontrib><creatorcontrib>Claire, Dromer</creatorcontrib><creatorcontrib>Espérie, Burnet</creatorcontrib><creatorcontrib>Eve, Camps</creatorcontrib><creatorcontrib>Antoine, Roux</creatorcontrib><title>Use of anti‐CMV immunoglobulins in lung transplant recipients: The French experience</title><title>Transplant infectious disease</title><addtitle>Transpl Infect Dis</addtitle><description>Rational
Pending the authorization of new anti‐CMV drugs with fewer adverse effects, exploring the possibilities offered by CMV immunoglobulins (CMVIG) seems necessary. In France, access to CMVIG requires official authorization by the national Health authority and is restricted to second line rescue therapy for CMV infection/disease. The aim of this multicenter retrospective study is to describe the indications and clinical situations that justified its use in France.
Methods
A multicenter retrospective study included 22 lung transplant patients over a 3‐year period. Data on clinical indication, tolerance and efficacy were collected.
Results
The main indication for CMVIG initiation, which was documented in 17 of them (82%) was complex clinical situations resulting from side effects to antiviral drug. CMVIG indication was documented as treatment for 15 patients (68%) and as a secondary prophylaxis for 7 patients (32%). Only one side effect (pruritus during infusion with no anaphylactic symptoms) attributable to CMVIG was reported. After CMVIG initiation, no recurrence of infection or disease was observed during a median follow‐up of 174 (12–682) days after treatment initiation for respectively 68% and 66% of the patients.
Conclusion
This study describes an unusual indication of CMVIG use as a last resort treatment in complex situations, based on clinical needs. CMVIG could be useful to change the course of CMV infection with minimal adverse effects or comorbidity.</description><subject>alternative therapeutics</subject><subject>Anaphylaxis</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - adverse effects</subject><subject>CMV</subject><subject>CMVIG</subject><subject>Cytomegalovirus</subject><subject>Cytomegalovirus Infections - drug therapy</subject><subject>Cytomegalovirus Infections - prevention & control</subject><subject>Health services</subject><subject>hematological toxicity</subject><subject>Humans</subject><subject>Immunoglobulins</subject><subject>Immunoglobulins - therapeutic use</subject><subject>Immunoglobulins, Intravenous - adverse effects</subject><subject>Immunological tolerance</subject><subject>Indication</subject><subject>Infections</subject><subject>Life Sciences</subject><subject>Lung</subject><subject>lung transplant, rescue treatment</subject><subject>Lung transplantation</subject><subject>Lung Transplantation - adverse effects</subject><subject>Lung transplants</subject><subject>Lungs</subject><subject>Patients</subject><subject>Prophylaxis</subject><subject>Pruritus</subject><subject>Retrospective Studies</subject><subject>Side effects</subject><subject>Signs and symptoms</subject><subject>Transplant Recipients</subject><issn>1398-2273</issn><issn>1399-3062</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctO3DAUhq0KVOjQRV-gssQGFgFf4lt3aLhKU7EZ2FqO4zBGiZPaCZcdj9Bn7JPUw1AqVerZnKNfn_5zjn4AvmB0hHMdj74-wlSw8gPYxVSpgiJOtl5nWRAi6A74lNI9QlioUn0EO7QUhJaI7YLbm-Rg30ATRv_r5ef8-y30XTeF_q7tq6n1IUEfYDuFOzhGE9LQZhJGZ_3gXRjTN7hcOXgeXbAr6J4GF7Ns3R7Ybkyb3Oe3PgM352fL-WWxuL64mp8sCkulKIuyrA2nyFIkOeM1UpxhQRqMcFUpaSSXjDHJkHCVYpgZIa2sWMNJbU0lGKUzcLjxXZlWD9F3Jj7r3nh9ebLQaw1RRkqm5APO7MGGHWL_Y3Jp1J1P1rX5I9dPSROmMMGSEZnR_X_Q-36KIX-iCceEK0SQ-rvcxj6l6Jr3CzDS62B0Dka_BpPZr2-OU9W5-p38k0QGjjfAo2_d8_-d9PLqdGP5GyzPlUc</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Charlotte, Roy</creator><creator>François, Parquin</creator><creator>Jonathan, Messika</creator><creator>Véronique, Boussaud</creator><creator>Olivier, Brugière</creator><creator>Tristan, Degot</creator><creator>Séverine, Feuillet</creator><creator>Jérôme, Lepavec</creator><creator>Adrien, Tissot</creator><creator>Claire, Dromer</creator><creator>Espérie, Burnet</creator><creator>Eve, Camps</creator><creator>Antoine, Roux</creator><general>Wiley Subscription Services, Inc</general><general>Wiley</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-2123-3527</orcidid><orcidid>https://orcid.org/0000-0001-8274-7180</orcidid><orcidid>https://orcid.org/0000-0002-3259-6430</orcidid></search><sort><creationdate>202112</creationdate><title>Use of anti‐CMV immunoglobulins in lung transplant recipients: The French experience</title><author>Charlotte, Roy ; François, Parquin ; Jonathan, Messika ; Véronique, Boussaud ; Olivier, Brugière ; Tristan, Degot ; Séverine, Feuillet ; Jérôme, Lepavec ; Adrien, Tissot ; Claire, Dromer ; Espérie, Burnet ; Eve, Camps ; Antoine, Roux</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3874-44da630c308656d0965172f101bb98a8685558507eb9515a78c8b5f62dcab7533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>alternative therapeutics</topic><topic>Anaphylaxis</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - adverse effects</topic><topic>CMV</topic><topic>CMVIG</topic><topic>Cytomegalovirus</topic><topic>Cytomegalovirus Infections - drug therapy</topic><topic>Cytomegalovirus Infections - prevention & control</topic><topic>Health services</topic><topic>hematological toxicity</topic><topic>Humans</topic><topic>Immunoglobulins</topic><topic>Immunoglobulins - therapeutic use</topic><topic>Immunoglobulins, Intravenous - adverse effects</topic><topic>Immunological tolerance</topic><topic>Indication</topic><topic>Infections</topic><topic>Life Sciences</topic><topic>Lung</topic><topic>lung transplant, rescue treatment</topic><topic>Lung transplantation</topic><topic>Lung Transplantation - adverse effects</topic><topic>Lung transplants</topic><topic>Lungs</topic><topic>Patients</topic><topic>Prophylaxis</topic><topic>Pruritus</topic><topic>Retrospective Studies</topic><topic>Side effects</topic><topic>Signs and symptoms</topic><topic>Transplant Recipients</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Charlotte, Roy</creatorcontrib><creatorcontrib>François, Parquin</creatorcontrib><creatorcontrib>Jonathan, Messika</creatorcontrib><creatorcontrib>Véronique, Boussaud</creatorcontrib><creatorcontrib>Olivier, Brugière</creatorcontrib><creatorcontrib>Tristan, Degot</creatorcontrib><creatorcontrib>Séverine, Feuillet</creatorcontrib><creatorcontrib>Jérôme, Lepavec</creatorcontrib><creatorcontrib>Adrien, Tissot</creatorcontrib><creatorcontrib>Claire, Dromer</creatorcontrib><creatorcontrib>Espérie, Burnet</creatorcontrib><creatorcontrib>Eve, Camps</creatorcontrib><creatorcontrib>Antoine, Roux</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Transplant infectious disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Charlotte, Roy</au><au>François, Parquin</au><au>Jonathan, Messika</au><au>Véronique, Boussaud</au><au>Olivier, Brugière</au><au>Tristan, Degot</au><au>Séverine, Feuillet</au><au>Jérôme, Lepavec</au><au>Adrien, Tissot</au><au>Claire, Dromer</au><au>Espérie, Burnet</au><au>Eve, Camps</au><au>Antoine, Roux</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of anti‐CMV immunoglobulins in lung transplant recipients: The French experience</atitle><jtitle>Transplant infectious disease</jtitle><addtitle>Transpl Infect Dis</addtitle><date>2021-12</date><risdate>2021</risdate><volume>23</volume><issue>6</issue><spage>e13754</spage><epage>n/a</epage><pages>e13754-n/a</pages><issn>1398-2273</issn><eissn>1399-3062</eissn><abstract>Rational
Pending the authorization of new anti‐CMV drugs with fewer adverse effects, exploring the possibilities offered by CMV immunoglobulins (CMVIG) seems necessary. In France, access to CMVIG requires official authorization by the national Health authority and is restricted to second line rescue therapy for CMV infection/disease. The aim of this multicenter retrospective study is to describe the indications and clinical situations that justified its use in France.
Methods
A multicenter retrospective study included 22 lung transplant patients over a 3‐year period. Data on clinical indication, tolerance and efficacy were collected.
Results
The main indication for CMVIG initiation, which was documented in 17 of them (82%) was complex clinical situations resulting from side effects to antiviral drug. CMVIG indication was documented as treatment for 15 patients (68%) and as a secondary prophylaxis for 7 patients (32%). Only one side effect (pruritus during infusion with no anaphylactic symptoms) attributable to CMVIG was reported. After CMVIG initiation, no recurrence of infection or disease was observed during a median follow‐up of 174 (12–682) days after treatment initiation for respectively 68% and 66% of the patients.
Conclusion
This study describes an unusual indication of CMVIG use as a last resort treatment in complex situations, based on clinical needs. CMVIG could be useful to change the course of CMV infection with minimal adverse effects or comorbidity.</abstract><cop>Denmark</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34723405</pmid><doi>10.1111/tid.13754</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-2123-3527</orcidid><orcidid>https://orcid.org/0000-0001-8274-7180</orcidid><orcidid>https://orcid.org/0000-0002-3259-6430</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1398-2273 |
| ispartof | Transplant infectious disease, 2021-12, Vol.23 (6), p.e13754-n/a |
| issn | 1398-2273 1399-3062 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_03524598v1 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | alternative therapeutics Anaphylaxis Antiviral agents Antiviral Agents - adverse effects CMV CMVIG Cytomegalovirus Cytomegalovirus Infections - drug therapy Cytomegalovirus Infections - prevention & control Health services hematological toxicity Humans Immunoglobulins Immunoglobulins - therapeutic use Immunoglobulins, Intravenous - adverse effects Immunological tolerance Indication Infections Life Sciences Lung lung transplant, rescue treatment Lung transplantation Lung Transplantation - adverse effects Lung transplants Lungs Patients Prophylaxis Pruritus Retrospective Studies Side effects Signs and symptoms Transplant Recipients |
| title | Use of anti‐CMV immunoglobulins in lung transplant recipients: The French experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A23%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20anti%E2%80%90CMV%20immunoglobulins%20in%20lung%20transplant%20recipients:%20The%20French%20experience&rft.jtitle=Transplant%20infectious%20disease&rft.au=Charlotte,%20Roy&rft.date=2021-12&rft.volume=23&rft.issue=6&rft.spage=e13754&rft.epage=n/a&rft.pages=e13754-n/a&rft.issn=1398-2273&rft.eissn=1399-3062&rft_id=info:doi/10.1111/tid.13754&rft_dat=%3Cproquest_hal_p%3E2591218528%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2612690209&rft_id=info:pmid/34723405&rfr_iscdi=true |